JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265281

Human DHCR7 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

DHCR7 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 3. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Sanger Sequencing - Human DHCR7 knockout HeLa cell line (AB265281)
  • Sanger seq

Unknown

Sanger Sequencing - Human DHCR7 knockout HeLa cell line (AB265281)

Homozygous : 1 bp insertion in exon 3.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 3

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265281-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265281-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265281 Human DHCR7 knockout HeLa cell line", "number":"AB265281-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265281-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265281-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265281 Human DHCR7 knockout HeLa cell line", "number":"AB265281-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265281-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265281 Human DHCR7 knockout HeLa cell line", "number":"AB265281-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265281-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265281 Human DHCR7 knockout HeLa cell line", "number":"AB265281-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
DHCR7
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

7-dehydrocholesterol reductase (DHCR7) is an enzyme that plays an important role in cholesterol biosynthesis. It catalyzes the conversion of 7-dehydrocholesterol (7-DHC) to cholesterol in the final step of the process. DHCR7 is also known by the name sterol Δ7-reductase. The enzyme has a molecular mass of approximately 54 kDa. Expression of DHCR7 is prominent in tissues that require active cholesterol synthesis such as the liver adrenal glands and brain.
Biological function summary

DHCR7 activity ensures the maintenance of cholesterol homeostasis in cells. The enzyme operates independently and does not form part of a larger complex focusing directly on the reduction of the double bond in the C7-8 position of 7-DHC to yield cholesterol. By regulating cholesterol levels DHCR7 supports membrane fluidity and integrity contributing to the proper function of cellular structures.

Pathways

DHCR7 is an important component of the cholesterol biosynthesis pathway which is part of the larger sterol metabolic pathway. Its function is linked with other enzymes such as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) highlighting their roles in sequential steps that convert squalene into cholesterol. These interactions highlight the interdependence of DHCR7 with other sterol-processing proteins influencing both cholesterol production and regulation within the body.

DHCR7 mutations can cause conditions such as Smith-Lemli-Opitz syndrome a congenital disorder characterized by multiple physical and developmental abnormalities. This condition connects DHCR7 to defective cholesterol metabolism and accumulation of toxic 7-DHC levels. Additionally the involvement of DHCR7 in cholesterol homeostasis ties it with potential dyslipidemias where abnormal lipid levels may influence cardiovascular health. Changes in DHCR7 function can lead to disruptions in normal cholesterol synthesis impacting related proteins and enzymatic pathways.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com